BIOMARIN PHARMACEUTICAL INC Significant Acquisitions and Disposals, Acquisition Costs or Sale Proceeds (Deprecated 2015-01-31)
BIOMARIN PHARMACEUTICAL INC (BMRN) had Significant Acquisitions and Disposals, Acquisition Costs or Sale Proceeds (Deprecated 2015-01-31) of $50.40 million as of 2011-08-31, per its 10-K filed 2012-02-22.
Discontinued › Notes
us-gaap:SignificantAcquisitionsAndDisposalsAcquisitionCostsOrSaleProceeds · last filed 2012-02-22
- 2011-08-31: Significant Acquisitions and Disposals, Acquisition Costs or Sale Proceeds (Deprecated 2015-01-31) $50.40M.
- 2011-06-22: Significant Acquisitions and Disposals, Acquisition Costs or Sale Proceeds (Deprecated 2015-01-31) $48.50M.
| Period end | Significant Acquisitions and Disposals, Acquisition Costs or Sale Proceeds (Deprecated 2015-01-31) |
|---|---|
| 2011-08-31 | $50.40M 10-K · filed 2012-02-22 |
| 2011-06-22 | $48.50M 10-Q · filed 2011-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |